← Back to Search

Fixed-dose Combination Tablet

HL040XC(Atorvastatin+Losartan) for High Cholesterol

Phase 1
Waitlist Available
Research Sponsored by HanAll BioPharma Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0~48hr
Awards & highlights
Approved for 30 Other Conditions
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

The objective of this study is: To evaluate the pharmacokinetics and safety of an experimental combination tablet containing 20 mg atorvastatin and 50 mg losartan potassium when administered orally as a single dose to healthy male subjects, compared with the concomitant administration of 20 mg atorvastatin and 50 mg losartan potassium tablets.

Eligible Conditions
  • High Cholesterol
  • High Blood Pressure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0~48hr
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0~48hr for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
AUC
Cmax

Awards & Highlights

Approved for 30 Other Conditions
This treatment demonstrated efficacy for 30 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: HL040XC(Atorvastatin+Losartan)Experimental Treatment1 Intervention
HL040XC lag time released combination drug
Group II: Losartan + AtorvastatinActive Control1 Intervention
Coadministration group
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Atorvastatin
FDA approved

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

HanAll BioPharma Co., Ltd.Lead Sponsor
16 Previous Clinical Trials
2,699 Total Patients Enrolled
~2 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top